A study led by Johns Hopkins Medicine found that the drug RK-33 shows promise in treating breast cancer that has spread to the bone. Patients with this condition have limited treatment options, leading to palliative care for managing symptoms. The drug targets and inhibits the protein DDX3, which is elevated in cancer cells, preventing growth and spread. In experiments with mice, RK-33 eliminated bone metastases and prevented cancer spread. Researchers plan to move forward with clinical trials for RK-33. This study represents a significant advancement in utilizing targeted therapies for aggressive cancers lacking specific treatments. Funding for the study was supported by the Flight Attendant Medical Research Institute.
Source link
Experimental drug RK-33 shows promise in treating breast cancer bone metastasis
